Compare Enveric Biosciences Inc (ENVB) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Plby Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Plby Group Inc trades at $1 (market cap $122.20M). The key difference: Plby Group Inc is far larger — about 18.3× Enveric Biosciences Inc's market cap, and Plby Group Inc is more actively traded (228,361 versus 41,141). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Plby Group Inc for 24 Days on average.
| ENVB | PLBY | |
|---|---|---|
Market Cap | $6.69M | $122.20M |
Volume | 41,141 | 228,361 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $2.71 |
52-Week Low | $1.27 | $0.99 |
Typical Hold Time | 14 Days | 24 Days |
Enterprise Value | -$1.60M | $267.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
PLBY Group trades at $0.99, down 5.12% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses from -$278M in 2022 to -$13M in 2025. Positive operating cash flow of $18K in 2025 marks a turnaround from previous negative figures. Recent leadership appointments signal strategic focus on brand growth.
While analyst consensus remains bullish (75% buy ratings), high debt levels and negative shareholder equity pose significant risks. The path to sustained profitability depends on successful execution of licensing and media strategies. Near-term catalysts include Q3 2026 earnings where the company faces a $0.01 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
